Does SECUKINUMAB Cause Bladder transitional cell carcinoma? 6 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Bladder transitional cell carcinoma have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.0% of all adverse event reports for SECUKINUMAB.
6
Reports of Bladder transitional cell carcinoma with SECUKINUMAB
0.0%
of all SECUKINUMAB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From SECUKINUMAB?
Of the 6 reports, 1 (16.7%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does SECUKINUMAB Cause?
Drug ineffective (27,434)
Psoriasis (21,976)
Pain (15,244)
Arthralgia (13,769)
Fatigue (9,406)
Psoriatic arthropathy (8,900)
Pruritus (8,755)
Malaise (8,570)
Rash (8,023)
Condition aggravated (7,536)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which SECUKINUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
SECUKINUMAB vs SELADELPAR LYSINE
SECUKINUMAB vs SELEGILINE
SECUKINUMAB vs SELENIUM
SECUKINUMAB vs SELENIUM SULFIDE
SECUKINUMAB vs SELEXIPAG